Silence Therapeutics (SLN) Sets New 12-Month Low at $110.00
Silence Therapeutics plc (LON:SLN)’s share price hit a new 52-week low during mid-day trading on Thursday . The stock traded as low as GBX 110 ($1.40) and last traded at GBX 112.50 ($1.44), with a volume of 3907 shares trading hands. The stock had previously closed at GBX 116 ($1.48).
Separately, Peel Hunt reiterated a “buy” rating on shares of Silence Therapeutics in a research report on Tuesday, July 3rd.
About Silence Therapeutics (LON:SLN)
Silence Therapeutics plc focuses on the discovery, development, and delivery of novel RNA therapeutics. The company designs short interfering RNA (siRNA) molecules that trigger the RNAi pathway and mediate the degradation of specific target messenger RNAs. It is developing various candidates for the treatment of cancer, iron overload disorders, cardiovascular disease, alcohol use disorder, and other metabolic diseases.
Featured Story: Are Wall Street analysts’ stock ratings worth following?
Receive News & Ratings for Silence Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Silence Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.